Clinical and regulatory intelligence for Acute Promyelocytic Leukemia with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 2

Relevant assets

Lisaftoclax →

QTX-2101 →

Relevant companies

Quetzal Therapeutics →

Recent signals(2)

ClinicalAugust 20, 2026

Quetzal Therapeutics initiates Phase 3 trial of QTX-2101 for Acute Promyelocytic Leukemia

Quetzal Therapeutics is conducting Phase 3 clinical trial to evaluate QTX-2101 in combination with ATRA for low-risk APL.

ClinicalJuly 6, 2026

Lisaftoclax Evaluated for Preventing Differentiation Syndrome in APL Patients

A clinical trial is underway to evaluate the efficacy and safety of Lisaftoclax in preventing differentiation syndrome in patients with acute promyelocytic leukemia receiving ATRA/ATO treatment.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Acute Promyelocytic Leukemia →

Hematology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.